NeoImmuneTech, Inc.
KOE: 950220.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Luke Yun Suk Oh
- Employees
- 82
- Headquarters
- Rockville, United States
- IPO year
- 2021
- Market cap
- ₩9.5B
- Website
- https://www.neoimmunetech.com
Loading 950220…
Loading profile data…Frequently asked questions about 950220
What does NeoImmuneTech, Inc. (950220.KQ) do?
NeoImmuneTech, Inc., a clinical-stage T cell-focused biotech company, develops and sells immuno-therapeutics. It is developing NT-I7, a clinical-stage long-acting human IL-7 for oncologic and infectious diseases. The company was incorporated in 2014 and is headquartered in Rockville, Maryland.
Where does 950220.KQ trade?
NeoImmuneTech, Inc. (950220.KQ) trades on the KOSDAQ.
What sector is 950220.KQ in?
NeoImmuneTech, Inc. (950220.KQ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NeoImmuneTech, Inc.?
Luke Yun Suk Oh is the chief executive officer of NeoImmuneTech, Inc. (950220.KQ).
Where is NeoImmuneTech, Inc. headquartered?
NeoImmuneTech, Inc. is headquartered in United States.
Does 950220.KQ pay a dividend?
NeoImmuneTech, Inc. (950220.KQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 950220.KQ go public?
NeoImmuneTech, Inc. (950220.KQ) completed its initial public offering in 2021.